Terrie Gibson, MD
Interventional Cardiology · Oklahoma City, OKNPI 1770587784
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,727 of the $4,425 with a category attached, or 61.6%. 23 manufacturers reported payments, led by Medtronic at 43.8% of the total. Reporting peaked in 2019 at $2,432 and has fallen 82.6% since, to $423 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OK, where the typical reported total is $7,360.
Across 135 payments — averaging $32.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Johnson & Johnson$584
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$349
- Kestra Medical Technology Services, Inc.$245
- Abbott$245
- E.r. Squibb & Sons, L.L.C.$176
- plus $887 from 17 others
Across 2 payments — averaging $1950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$4K
What the payments were for
- Travel & lodging$1,69938%
- Food & beverage$2,72762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 7 | $1,940 |
| Johnson & Johnson | 40 | $584 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $349 |
| Kestra Medical Technology Services, Inc. | 11 | $245 |
| Abbott | 4 | $245 |
| E.r. Squibb & Sons, L.L.C. | 12 | $176 |
| Penumbra, Inc. | 1 | $159 |
| Novartis | 8 | $137 |
| Amgen | 6 | $118 |
| Abiomed | 3 | $104 |
| Boehringer Ingelheim | 4 | $79 |
| Philips North America LLC | 5 | $67 |
| Boston Scientific | 3 | $58 |
| Actelion Pharmaceuticals US, Inc. | 2 | $26 |
| Shockwave Medical, Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Novo Nordisk | 1 | $13 |
| AbbVie | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$159
- Confirm Rx$101
How this compares
$4,425 in reported general payments places this provider in the 35th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 394 | $400,904 |
| EntrestoSacubitril/Valsartan | 234 | $244,100 |
| XareltoRivaroxaban | 125 | $141,890 |
| Repatha SureclickEvolocumab | 79 | $80,202 |
| Praluent PenAlirocumab | 41 | $32,295 |
| BrilintaTicagrelor | 29 | $30,901 |
| JardianceEmpagliflozin | 28 | $23,198 |
| LivaloPitavastatin Calcium | 23 | $16,018 |
| FarxigaDapagliflozin Propanediol | 17 | $12,451 |
| Repatha PushtronexEvolocumab | 14 | $8,069 |
| Nebivolol Hcl | 122 | $7,607 |
| Atorvastatin Calcium | 607 | $7,586 |
| Metoprolol Succinate | 510 | $7,552 |
| Ranolazine ErRanolazine | 67 | $4,691 |
| Prasugrel Hcl | 47 | $4,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $137 | $244,100234 claims |
| Johnson & JohnsonXarelto | $584 | $141,890125 claims |
| AstraZenecaBrilinta, Farxiga | $15 | $43,35246 claims |
| Boehringer IngelheimJardiance | $79 | $23,19828 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $17 | $16,01823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.